Liminatus Pharma, Inc. aksje
LIMN
After-hours$0.1801+0.0161 (+9.82%)
Post-Market:$0.1997+0.02 (+10.88%)
Laster graf...
Liminatus Pharma, Inc.
Market Cap
$8,082,461
Åpning0.1671
Høy0.1875
Lav0.1660
Volum6.76M
P/EN/A
Markedsverdi8.08M
52-ukers høy33.6600
52-ukers lav0.1320
Gj.sn. volum9.73M
UtbytteN/A
Beta0.76
EPS-0.2500
Om Liminatus Pharma, Inc. aksje
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Selskapsinformasjon
Børs: NasdaqGM (NGM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
12611 Hiddencreek Way
90703 Cerritos, United States
90703 Cerritos, United States
Telefon: + 213 273 5453
Nettside: https://liminatuspharma.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Laveste kursmål
Gjennomsnittlig kursmål
Median kursmål
Høyeste kursmål